Franco Buzzi
- Internal Medicine top 1%
- Oncology top 2%
- Cancer Treatment and Pharmacology 15
- Colorectal Cancer Treatments and Studies 12
- Lung Cancer Research Studies 4
- Cancer Research top 5%
- Breast Cancer Treatment Studies 6
- Emergency Medical Services top 2%
- Genetics top 5%
- Estrogen and related hormone effects 9
-
- Lung Cancer Treatments and Mutations 8
- Gastric Cancer Management and Outcomes 5
-
- Cancer therapeutics and mechanisms 4
Franco Buzzi
42 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Internal Medicine 412
- Oncology 1.0k
- Cancer Research 555
- Emergency Medical Services 204
- Genetics 658
Countries citing papers authored by Franco Buzzi
This map shows the geographic impact of Franco Buzzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franco Buzzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franco Buzzi more than expected).
Fields of papers citing papers by Franco Buzzi
This network shows the impact of papers produced by Franco Buzzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franco Buzzi. The network helps show where Franco Buzzi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Franco Buzzi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studybreakdown → | 2009 | 446 |
| 2 | 2007 | 19 | |
| 3 | 2006 | 158 | |
| 4 | 2005 | 38 | |
| 5 | 2004 | 54 | |
| 6 | 2004 | 29 | |
| 7 | 2003 | 61 | |
| 8 | 2003 | 17 | |
| 9 | 2002 | 23 | |
| 10 | [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. | 1999 | 1 |
| 11 | 1998 | 206 | |
| 12 | 1993 | 18 | |
| 13 | 1992 | 180 | |
| 14 | 1991 | 1 | |
| 15 | 1990 | 18 | |
| 16 | 1990 | 40 | |
| 17 | 1989 | 19 | |
| 18 | 1989 | 10 | |
| 19 | 1988 | 10 | |
| 20 | 1983 | 5 |
About Franco Buzzi
Franco Buzzi is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics and Internal Medicine, having authored 42 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (15 papers), Colorectal Cancer Treatments and Studies (12 papers), Estrogen and related hormone effects (9 papers), Lung Cancer Treatments and Mutations (8 papers), Breast Cancer Treatment Studies (6 papers), Gastric Cancer Management and Outcomes (5 papers), Lung Cancer Research Studies (4 papers) and Cancer therapeutics and mechanisms (4 papers). The work is most often cited by research in Internal Medicine (412 citations), Oncology (1.0k citations), Cancer Research (555 citations), Emergency Medical Services (204 citations) and Genetics (658 citations). Franco Buzzi has collaborated with scholars based in Italy, United Kingdom and United States. Frequent co-authors include Maurizio Tonato, B. Massidda, P Sismondi, Erminio Bonizzoni, Mario Mandalà, Melina Verso, Sergio Ricci, A. Rubagotti, Gualberto Gussoni and Rodolfo Passalacqua. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, Cancer and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.